All Articles

Manulife announced its estimated 2025 reinvested ETF capital gains. Learn what this "phantom income" means for your portfolio and your tax bill.

Manulife's estimated December ETF distributions are out, offering a crucial glimpse for income seekers planning for 2026 in a complex market.

RAID's blockbuster crossover with Alien and Predator isn't just fan service. It's a calculated strategy driving revenue and redefining player engagement.

With a leaner profile, BioLineRx bets on a novel glioblastoma drug while advancing its diverse pipeline. A deep dive into the strategy and the science.

Aldebaran Resources reveals a robust economic study for its Altar copper mine, but the news is eclipsed by a key partner's surprise withdrawal.

Sarepta's clinical progress in myotonic dystrophy signals a major diversification beyond Duchenne, leveraging a high-stakes siRNA partnership.

A Colorado cybersecurity firm's radical shift to a 32-hour week is boosting client satisfaction. Is this a new blueprint for high-stakes industries?

Quebec's new legal vape market is more than just products; it's a case study in building the regulatory infrastructure to tame a massive illicit trade.

Despite an FDA-approved product, Clearside Biomedical files for Chapter 11, putting its revolutionary eye-drug tech and a Phase 3 asset up for grabs.

After selling its first FDA-approved drug, Seres Therapeutics pivots to its next-gen candidate, SER-155, facing a make-or-break moment for its future.

With a $700M oversubscribed funding round, X-energy is attracting serious investors. Is this the moment advanced nuclear power finally goes mainstream?

While rivals bleed cash, Cannara Biotech posts record profits. We dissect its disciplined strategy of regional dominance and operational excellence.

A small firm's win in a U.S. Army contest reveals a radical new approach to rapidly deploying AI-powered defenses against the growing drone threat.

A new deal between Renault and telematics leader Ituran is set to redefine vehicle security and connectivity for millions across Latin America.

As Genmab's CFO prepares for a key fireside chat, investors are watching closely. Will its strategic bets on M&A and pipeline assets pay off?

A junior explorer's stunning high-grade discovery in the Canadian Arctic promises a new source of critical metals, but can it overcome the North's immense hurdles?

A modest $350K private placement reveals Vaxil Bio's deep identity crisis as it looks beyond its orphan drug asset for a new path to survival.

In its first major move post-IPO, Atmus acquires Koch Filter, targeting high-growth industrial air filtration for data centers and healthcare.

Aquestive Therapeutics signals commercial readiness for its needle-free allergy film, setting up a high-stakes showdown in the multi-billion dollar market.

As cyber threats escalate in Latin America, one company's strategic acquisitions and localized approach are setting a new standard for regional defense.